A multicomponent outreach program increased completion of the three-dose human papillomavirus vaccination series that reduces the risk of cervical cancer, according to a joint study by UT Southwestern Medical Center and Parkland Health & Hospital System.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
